STERIS plc

STE ·Healthcare, Medical Devices, Ireland

STERIS plc (STE)

Overview

STERIS plc is a global provider of infection prevention and other procedural products and services, primarily serving the healthcare, pharmaceutical, and medical device industries. Legally headquartered in Dublin, Ireland (a 2018 relocation for tax purposes, following a 2014 tax-inversion combination with UK-based Synergy Health), STERIS runs its principal operating headquarters in Mentor, Ohio, and traces its roots to a 1985 Ohio startup originally called Innovative Medical Technologies. The company is a member of the S&P 500 and classified in the Medical Devices industry within Healthcare. For fiscal year 2025 (ended March 31, 2025), STERIS generated roughly $5.5 billion in revenue from continuing operations (up 6% year over year), with net income around $610 million, and it employs approximately 18,000 people worldwide.

What They Do & How They Make Money

STERIS makes money by selling and servicing the equipment, consumables, and outsourced services that hospitals, pharmaceutical manufacturers, and medical device companies rely on to keep instruments, environments, and products sterile and safe. Its business mixes capital equipment sales (sterilizers, washers, surgical tables, endoscopy reprocessing systems) with recurring, higher-margin revenue streams: single-use and consumable chemistries, instrument and equipment repair and maintenance contracts, and outsourced or contract sterilization services billed per batch or on service agreements. This recurring-revenue tilt — service and consumables now make up the majority of sales — smooths out the lumpiness of large capital equipment purchases and gives STERIS durable, repeat relationships with hospital sterile-processing departments, operating rooms, and biopharma manufacturing sites. A meaningful share of revenue also comes from contract sterilization, where STERIS operates dozens of facilities that sterilize medical devices (via ethylene oxide, gamma, or electron-beam/X-ray processes) and pharmaceutical products on behalf of manufacturers who don't want to build or run their own sterilization infrastructure — a capital-intensive, highly regulated niche with high barriers to entry.

Business Segments

STERIS reports three segments:

Healthcare — By far the largest segment. Sells and services equipment and consumables for hospital sterile processing departments and procedural areas (operating rooms, endoscopy suites): sterilizers, washers/disinfectors, cleaning chemistries, endoscope reprocessing systems, surgical tables and lights, connectivity/OR-integration solutions, and instrument repair and outsourced reprocessing services. Revenue mix within the segment spans capital equipment, consumables, and service, with service and consumables growing faster than capital equipment in recent periods.
Applied Sterilization Technologies (AST) — Contract sterilization and lab testing for medical device and pharmaceutical manufacturers, using ethylene oxide, gamma irradiation, electron beam, and X-ray modalities across a network of facilities in the Americas, Europe, and Asia. This is STERIS's fastest-growing and highest-margin segment, benefiting from rising global procedure volumes and device-manufacturer outsourcing trends; fiscal 2025 Q4 revenue grew ~9-10% organically.
Life Sciences — Equipment, consumables, and services supporting aseptic (sterile) manufacturing for biopharmaceutical and medical device production facilities: pharmaceutical-grade detergents, sterilizers, vaporized hydrogen peroxide decontamination systems, and water-for-injection generation systems, plus installation and maintenance services. This segment was affected in fiscal 2025 by the divestiture of the Cepheid/CECS-related business in April 2024, but its core consumables continued to grow.

STERIS previously also had a Dental segment (mainly infection-prevention products for dental practices, largely from the 2021 Cantel Medical acquisition), which has since been divested or wound down and no longer appears as a reporting segment.

Competitors

Competition varies significantly by segment:

Healthcare: 3M, Baxter International, Boston Scientific, Getinge, Olympus, and Stryker, among others, compete on sterilization/reprocessing equipment, surgical tables, and OR products.
Applied Sterilization Technologies: Sotera Health (Sterigenics) is the primary large competitor in contract sterilization, alongside a number of smaller regional contract-sterilization and testing firms.
Life Sciences: Getinge, Ecolab, Belimed, and Fedegari compete in aseptic manufacturing equipment and cleaning/decontamination chemistries.

Competitive Position

STERIS holds leading positions in most of the niches it competes in, particularly hospital sterile processing and contract sterilization (AST), where scale, regulatory track record, and the capital intensity/permitting difficulty of building new sterilization capacity (especially ethylene oxide facilities, which face environmental and community opposition) act as real barriers to new entrants. The company touts a strong quality and regulatory record — it reported no FDA enforcement actions and no Class I recalls in recent fiscal years — which matters enormously in a heavily regulated industry where a compliance failure can shut down a facility or trigger costly recalls. Its patent portfolio (over 600 U.S. patents, 2,400+ international) and decades of accumulated engineering know-how in sterilization science provide additional differentiation. The shift of revenue mix toward services and consumables gives STERIS more predictable, higher-margin cash flows and stickier customer relationships than a pure capital-equipment vendor would have.

Key risks include customer concentration in government-funded and increasingly cost-constrained healthcare systems, which can delay hospital capital equipment purchases; supply chain dependence on ethylene oxide and cobalt-60 (a byproduct of nuclear reactors, in limited global supply) for its AST sterilization operations; regulatory and environmental risk tied to ethylene oxide use, which has drawn EPA scrutiny and community/litigation pressure at various U.S. sites; and general macro and geopolitical risk (tariffs, inflation, currency) affecting a globally manufactured and sold product line. Competitively, STERIS faces both large diversified med-tech rivals (3M, Getinge, Stryker) with broader resources and smaller specialized players that can undercut on price in specific product categories, meaning STERIS must continue to invest in innovation and service quality to defend its premium positioning.